Araki Eiichi, Haneda Masakazu, Kasuga Masato, Nishikawa Takeshi, Kondo Tatsuya, Ueki Kohjiro, Kadowaki Takashi
Department of Metabolic Medicine, Kumamoto University, Kumamoto, Japan.
Asahikawa Medical University, Asahikawa, Japan.
J Diabetes Investig. 2017 Jan;8(1):123-125. doi: 10.1111/jdi.12600. Epub 2016 Dec 9.
In the 'Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013', a new concept of the glycemic control in patients with diabetes in Japan has been declared from the Japan Diabetes Society. The main objective value of HbA1c was set to <7% from the perspective of preventing microvascular complications. On the other hand, the objective in cases where objectives can be attained by appropriate dietary or exercise therapy, or during pharmacotherapy without the occurrence of side effects such as hypoglycemia was set to <6%, and the objective in cases where intensification of treatment was considered difficult due to side effects such as hypoglycemia or for other reasons was set to <8%. Treatment objectives should be established individually, in consideration of age, duration of disease, organ damage, risk of hypoglycemia, support structure, and etc.
在《2013年日本糖尿病治疗循证实践指南》中,日本糖尿病学会提出了日本糖尿病患者血糖控制的新概念。从预防微血管并发症的角度出发,糖化血红蛋白(HbA1c)的主要目标值设定为<7%。另一方面,对于通过适当饮食或运动疗法即可实现目标,或在药物治疗期间未发生低血糖等副作用的情况,目标设定为<6%;而对于因低血糖等副作用或其他原因难以强化治疗的情况,目标设定为<8%。应根据年龄、病程、器官损害、低血糖风险、支持体系等因素,为患者个体制定治疗目标。